← Back to all signals
ABT · Q2 2026

ABBOTT LABORATORIES

Reported 2026-07-16
IN-LINE
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Solid execution, raised EPS guidance, and strong portfolio momentum signal accelerated growth ahead.

  • ✓Guidance was raised, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Mixed evidence

The headline and management signals do not point in one direction (confidence rising).

EPS: reported vs expected+1.4%$1.31 vs $1.29
Revenue: reported vs expected—— vs —
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate

Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.

Premium intelligence

The evidence behind the signal

Full report
Management language

Why confidence moved

“Our second-quarter results reflect the momentum we are building”
“We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”
“Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance”
Guidance specificity
90/100

High specificity

Abbott raised full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60 and reaffirmed comparable sales growth guidance of 6.5% to 7.5%.

Pressure point
!

Foreign exchange volatility impacting reported

0 potential deflections detected in management communication.

Narrative break

What changed

Completion of the Exact Sciences acquisition on March 23, 2026, establishing the new Cancer Diagnostics business.

Q&A evidence

Management responses

No material Q&A deflections were detected.

Key positives
  • Reported second-quarter sales growth of 13.0 percent with strong underlying comparable sales growth of 4.8 percent.
  • Raised full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60.
  • Strong double-digit performance in key growth areas including Electrophysiology and the integration of Exact Sciences in Cancer Diagnostics.
Key risks
  • Foreign exchange volatility impacting reported international sales growth across segments.
  • Potential regulatory and integration execution risks associated with the Exact Sciences acquisition.
  • Lower sales volumes and pricing pressures in the Nutrition segment compared to prior year.
Topic velocity

Language versus prior quarter

M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition

What drove the EarnIQ score

Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0